Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana
Identifieur interne : 000716 ( PascalFrancis/Curation ); précédent : 000715; suivant : 000717Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana
Auteurs : Kwamena William Coleman Sagoe [Ghana] ; Afrakoma Adjoa Agyei [Ghana] ; Francesca Ziga [Ghana] ; Margaret Lartey [Ghana] ; Theophilus K. Adiku [Ghana] ; Makafui Seshi Max Q. Arens [États-Unis] ; Julius Abraham Addo Mingle [Ghana]Source :
- Journal of medical virology [ 0146-6615 ] ; 2012.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4+ undertaken within 1 month (n = 83), CD4+ count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P= 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4+ counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P= 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4+ count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4+ and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000191
Links to Exploration step
Pascal:12-0195630Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana</title>
<author><name sortKey="Coleman Sagoe, Kwamena William" sort="Coleman Sagoe, Kwamena William" uniqKey="Coleman Sagoe K" first="Kwamena William" last="Coleman Sagoe">Kwamena William Coleman Sagoe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Adjoa Agyei, Afrakoma" sort="Adjoa Agyei, Afrakoma" uniqKey="Adjoa Agyei A" first="Afrakoma" last="Adjoa Agyei">Afrakoma Adjoa Agyei</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Pharmacy Department, Korle-Bu Teaching Hospital</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K." last="Adiku">Theophilus K. Adiku</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Arens, Makafui Seshi Max Q" sort="Arens, Makafui Seshi Max Q" uniqKey="Arens M" first="Makafui Seshi Max Q." last="Arens">Makafui Seshi Max Q. Arens</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Retrovirus Laboratory, Department of Pediatrics, Washington University Medical School</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Addo Mingle, Julius Abraham" sort="Addo Mingle, Julius Abraham" uniqKey="Addo Mingle J" first="Julius Abraham" last="Addo Mingle">Julius Abraham Addo Mingle</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0195630</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0195630 INIST</idno>
<idno type="RBID">Pascal:12-0195630</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000191</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000716</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana</title>
<author><name sortKey="Coleman Sagoe, Kwamena William" sort="Coleman Sagoe, Kwamena William" uniqKey="Coleman Sagoe K" first="Kwamena William" last="Coleman Sagoe">Kwamena William Coleman Sagoe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Adjoa Agyei, Afrakoma" sort="Adjoa Agyei, Afrakoma" uniqKey="Adjoa Agyei A" first="Afrakoma" last="Adjoa Agyei">Afrakoma Adjoa Agyei</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Pharmacy Department, Korle-Bu Teaching Hospital</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K." last="Adiku">Theophilus K. Adiku</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Arens, Makafui Seshi Max Q" sort="Arens, Makafui Seshi Max Q" uniqKey="Arens M" first="Makafui Seshi Max Q." last="Arens">Makafui Seshi Max Q. Arens</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Retrovirus Laboratory, Department of Pediatrics, Washington University Medical School</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Addo Mingle, Julius Abraham" sort="Addo Mingle, Julius Abraham" uniqKey="Addo Mingle J" first="Julius Abraham" last="Addo Mingle">Julius Abraham Addo Mingle</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term>
<term>Antiretroviral agent</term>
<term>Antiviral</term>
<term>Epidemiology</term>
<term>Hepatitis</term>
<term>Hepatitis B virus</term>
<term>Hepatitis C virus</term>
<term>Human immunodeficiency virus</term>
<term>Mixed infection</term>
<term>Prevalence</term>
<term>Treatment</term>
<term>Viral load</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus hépatite C</term>
<term>Virus hépatite B</term>
<term>Virus immunodéficience humaine</term>
<term>Prévalence</term>
<term>Epidémiologie</term>
<term>Antiviral</term>
<term>Antirétroviral</term>
<term>Traitement</term>
<term>Charge virale</term>
<term>Hépatite</term>
<term>Infection mixte</term>
<term>SIDA</term>
<term>Antigène CD4</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4<sup>+</sup>
undertaken within 1 month (n = 83), CD4<sup>+</sup>
count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P= 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4<sup>+</sup>
counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P= 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4<sup>+</sup>
count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4<sup>+</sup>
and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0146-6615</s0>
</fA01>
<fA02 i1="01"><s0>JMVIDB</s0>
</fA02>
<fA03 i2="1"><s0>J. med. virol.</s0>
</fA03>
<fA05><s2>84</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>COLEMAN SAGOE (Kwamena William)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ADJOA AGYEI (Afrakoma)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ZIGA (Francesca)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LARTEY (Margaret)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ADIKU (Theophilus K.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ARENS (Makafui Seshi/ Max Q.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ADDO MINGLE (Julius Abraham)</s1>
</fA11>
<fA14 i1="01"><s1>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medicine, University of Ghana Medical School</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Pharmacy Department, Korle-Bu Teaching Hospital</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Retrovirus Laboratory, Department of Pediatrics, Washington University Medical School</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>6-10</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17422</s2>
<s5>354000509832130020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>3/4 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0195630</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of medical virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4<sup>+</sup>
undertaken within 1 month (n = 83), CD4<sup>+</sup>
count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P= 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4<sup>+</sup>
counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P= 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4<sup>+</sup>
count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4<sup>+</sup>
and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02J</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A05C06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus hépatite C</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Hepatitis C virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hepatitis C virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus hépatite B</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Hepatitis B virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hepatitis B virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antirétroviral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antiretroviral agent</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antiretroviral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Charge virale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Viral load</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Carga vírica</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Hépatite</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Hepatitis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hepatitis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Infection mixte</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Mixed infection</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Infección mixta</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>SIDA</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>AIDS</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>SIDA</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Antigène CD4</s0>
<s4>INC</s4>
<s5>79</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hepacivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Hepacivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hepacivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Immunodéficit</s0>
<s5>13</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Immune deficiency</s0>
<s5>13</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Inmunodeficiencia</s0>
<s5>13</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>17</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>17</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>17</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Pathologie de l'appareil digestif</s0>
<s5>18</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>18</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>18</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Pathologie du foie</s0>
<s5>19</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Hepatic disease</s0>
<s5>19</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Hígado patología</s0>
<s5>19</s5>
</fC07>
<fN21><s1>149</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000716 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000716 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaSubSaharaV1 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:12-0195630 |texte= Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Naive Patients With HIV Infection at a Major Treatment Center in Ghana }}
![]() | This area was generated with Dilib version V0.6.32. | ![]() |